Supplementary Materials

Supplementary Material for:

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Alessandro Prestipino, Alica J. Emhardt, Konrad Aumann, David O'Sullivan, Sivahari P. Gorantla, Sandra Duquesne, Wolfgang Melchinger, Lukas Braun, Slavica Vuckovic, Melanie Boerries, Hauke Busch, Sebastian Halbach, Sandra Pennisi, Teresa Poggio, Petya Apostolova, Pia Veratti, Michael Hettich, Gabriele Niedermann, Mark Bartholomä, Khalid Shoumariyeh, Jonas S. Jutzi, Julius Wehrle, Christine Dierks, Heiko Becker, Annette Schmitt-Graeff, Marie Follo, Dietmar Pfeifer, Jan Rohr, Sebastian Fuchs, Stephan Ehl, Frederike A. Hartl, Susana Minguet, Cornelius Miething, Florian H. Heidel, Nicolaus Kröger, Ioanna Triviai, Tilman Brummer, Jürgen Finke, Anna L. Illert, Eliana Ruggiero, Chiara Bonini, Justus Duyster, Heike L. Pahl, Steven W. Lane, Geoffrey R. Hill, Bruce R. Blazar, Nikolas von Bubnoff, Erika L. Pearce, Robert Zeiser*

*Corresponding author. Email: robert.zeiser{at}uniklinik-freiburg.de

Published 21 February 2018, Sci. Transl. Med. 10, eaam7729 (2018)
DOI: 10.1126/scitranslmed.aam7729

This PDF file includes:

  • Materials and Methods
  • Fig. S1. PD-L1 expression is increased in JAK2V617F primary mouse monocytes compared to WT mouse monocytes.
  • Fig. S2. Oncogenic JAK2V617F increases PD-L1 expression.
  • Fig. S3. Ruxolitinib treatment reduces serum IFN-γ in mice transplanted with JAK2V617F-transduced BM.
  • Fig. S4. PD-L1 expression is not affected by different activating mutations.
  • Fig. S5. The luciferase reporter assay vector maps are displayed.
  • Fig. S6. STAT3 and STAT5 activation increase PD-L1 expression.
  • Fig. S7. PD-L1 expression increases in human JAK2V617F-mutant cells.
  • Fig. S8. PD-L1 expression depends on the MPN disease stage.
  • Fig. S9. Transfer of JAK2V617F-mutant BM results in MPN features.
  • Fig. S10. Anti–PD-1 treatment does not increase GVHD scores.
  • Fig. S11. JAK2V617F-mutant Ba/F3 cells affect T cell metabolism and cell cycle.
  • Fig. S12. Anti–PD-1 treatment decreases disease burden of an MPN patient.

[Download PDF]